- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Moderate to severe ulcerative colitis. Severe juvenile idiopathic arthritis. Severe chronic plaque psoriasis. Severe Crohn disease. Vision-threatening non-infectious uveitis
- Meeting Date: March 2026
- Public Summary Document (PSD) March 2026 PBAC Meeting - (PDF)
- Public Summary Document (PSD) March 2026 PBAC Meeting - (DOCX)
Adalimumab – March 2026
Injection 20 mg in 0.2 mL single use pre-filled syringe
Last updated
11 March 2026